Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2021/22 Earnings Presentation
84 slides from Coloplast A/s Class B's earnings presentation, January 2022
Slide 1: Roadshow presentation Q1 2021/22
Roadshow presentation Q1 2021/22 Making life easier Kirsten, DK STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid start in Q1 with 6% organic growth and 32% EBIT margin
Solid start in Q1 with 6% organic growth and 32% EBIT margin1. Financial guidance updated to reflect the Atos Medical acquisition REVENUE GROWTH Q1 2021/22 highlights Reported revenue (mDKK) • Organic growth of 6% and reported growth in DKK of 9% Organic growth • Organic growth by business area: Ost
Slide 4: Q1 growth was driven by the European markets across all business areas
Q1 growth was driven by the European markets across all business areas Q1 2021/22 revenue by business area Q1 2021/22 revenue by geography Business Reported revenue Q1 Organic growth Share of organic Geographic Reported revenue Q1 Organic growth Share of organic area DKKm Q1 growth area DKKm Q1 grow
Slide 5: Atos Medical guidance is confirmed, and expected to contribute to Strive25 ambition
Atos Medical guidance is confirmed, and expected to contribute to Coloplast Strive25 ambition Outlook Atos Medical is expected Organic revenue to contribute to Coloplast’s 8-10% growth Strive25 long-term financial guidance 7-9% organic growth EBITDA margin Mid-30s +30% EBIT margin Page 5
Slide 6: Ostomy Care grew 6% organically in Q1
Ostomy Care grew 6% organically in Q1, driven by Europe, as well as Emerging markets excluding China Ostomy Care performance Q1 2021/22 highlights • Q1 organic growth was 6% and reported growth was 9% 12 • Growth was driven by Europe, as well as Emerging markets, excluding China 9 • Europe had a sol
Slide 7: Continence Care organic growth in Q1 was 5%
Continence Care organic growth in Q1 was 5%, driven mostly by Europe, as well as the US Continence Care performance Q1 2021/22 highlights • Q1 organic growth was 5% and reported growth was 8% • Growth was driven mostly by Europe; the US also contributed 9 • Europe was the main growth contributor, dr
Slide 8: Interventional Urology grew 5% organically in Q1
Interventional Urology grew 5% organically in Q1, driven by Women’s Health; negative impact from baseline in Men’s Health Interventional Urology performance Q1 2021/22 highlights • Q1 organic growth was 5% and reported growth was 8% 82 • Growth was driven by Women’s Health, and negatively impacted b
Slide 9: Wound & Skin Care grew 12% organically in Q1
Wound & Skin Care grew 12% organically in Q1, and Wound Care in isolation grew 17%, driven by solid momentum in Europe Wound & Skin Care performance Q1 2021/22 highlights • Q1 organic growth was 12%, and reported growth was 15% 20 • Wound Care in isolation grew 17% organically 17 17 15 • Main growth
Slide 10: Q1 reported growth was up 9%, above organic growth due to currencies
Q1 reported growth was up 9%, ~3%-points above organic growth due to positive impact from currencies, mainly GBP, USD and CNY Revenue development (DKKm) Q1 2021/22 highlights • Reported revenue increased by DKK 431 million, or 9% compared to Q1 2020/21 • Q1 organic growth was 6% or DKK 288 million 1
Slide 11: Reported EBIT margin of 32% in Q1
Reported EBIT margin1 of 32% in Q1 reflecting increased level of travel and marketing spend, partly offset by efficiency gains and FX EBIT margin development before special items (%) Q1 2021/22 highlights • Q1 gross margin was 68%, similar to Q1 last year 0.6 -1.2 • Positive impact from operating le
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments Q1 2021/22 highlights • Free cash flow was DKK 930 million compared to an outflow of DKK 14 million in Q1 2020/21 98 99 98 93 • Adjusted for the Nine Continents Medical acquisition last year, Q1 90 90 2020/21 free cash f
Slide 13: Financial guidance for FY 2021/22 updated with impact from Atos Medical
Financial guidance for FY 2021/22 updated with impact from the Atos Medical acquisition GUIDANCE 2021/22 GUIDANCE 2021/22 (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalized grow
Slide 14: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with full Syner
Slide 15: Introduction to Coloplast (excluding Atos Medical)
Making it easier Stina to be yourself LEADING INTIMATE HEALTHCARE Introduction to Coloplast (excluding Atos Medical)
Slide 16: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2020/21 by segment Group revenue 2020/21 by geography 1 Continence Care European 1 36% markets 58% Ostomy Care Other developed 40% markets DKK DKK 25% 19.4bn 19.4bn 4 5 Interventional Urology Emerging Wound & Skin Care 11
Slide 17: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs WHO ARE OUR TYPICAL USERS HOW DO WE HELP THEM? People who have had their intestine redirected to an SenSura® Mio Ostomy Care opening in the abdominal wall Ostomy bag People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 18: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 19: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 20: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Interventional Urology Wound Care Emerging Addressable market 18 - 19bn 14 - 15bn 12 - 13bn 22 - 24bn Size in DKK 4 - 5% 5 - 6% 3 - 5% 2 - 4% Growth in %* Coloplast
Slide 21: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future MACRO TRENDS IMPACT COMMERCIAL MODEL Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Payer preferen
Slide 22: Our Strive25 strategy will drive continued long-term value creation
Our Strive25 strategy will drive continued long-term value creation through revenue and earnings growth Chronic Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainability efficiency 1) Constant
Slide 23: Supporting sustainable development with emphasis on environmental performance
Supporting sustainable development with a strong emphasis on improving our environmental performance Our mission Making life easier for people with intimate healthcare needs Stina Our 2025 priority Our 2025 priority Improving Reducing products and emissions packaging 90% of packaging is recyclable N
Slide 24: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas Economics & We expect to invest up to 2% Innovation of revenue in incremental OPEX investments Government Market Chronic Care Attractiveness U
Slide 25: We will actively pursue M&A opportunities as a lever for growth
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic screening based Portfolio Channel Early stage Large plays expansion & expansion technologies adjacencies Page 25
Slide 26: Key enablers to support the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses COMMERCIAL MODEL KEY ENABLERS Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Payer prefe
Slide 27: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence Control and continuity of 1 product supply ~30% MS ~15% MS ~5% MS +30 countries 2 Target the full value p
Slide 28: Ambitious Clinical Performance Program to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? of users describe UTIs are their 45 %* 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 29: Significant progress across the Clinical Performance Program
We made significant progress across the Clinical Performance Program during 2020/21 Status October 2020 Status January 2021 Expected launch Product launch Digital ostomy - CE mark has been granted expected in first solution Pilot studies conducted with successful results ✓ - Payer pilot studies in G
Slide 30: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, % Cost item Development, in % of revenue -0.5%-points 28.7 29.0 28.7 28.2 28.9 28-30 Distribution +1.2%-points 67.3 67.7 68.0 68.5 68.3 ~68 -0.1%-point 4.0
Slide 31: Automation, procurement and scale are key to Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 9% ~800 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 21
Slide 32: Global Business Support and IT landscape enables scaling
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / accounting Master Data Labelling (Chronic
Slide 33: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and >30% R&D costs especially dri
Slide 34: Continued strong development in free cash flow during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 6% 5% 4% 4% 4% 5% 4% 4% 4% 3% 25% ~24% 4% 1,016 23% 23
Slide 35: Attractive cash returns despite large investments
We will continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Highlights Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liquidity to share
Slide 36: In sum, stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 32% • Stable market trends in our Chronic Care business 10% 6% • Strong Coloplast Care retention program 9% and innovative DtC activities 06/07 08/09 10/1
Slide 37: Introduction to Atos Medical
Introduction to Atos Medical Stina the global market leader in laryngectomy
Slide 38: Atos Medical is the global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Atos key business highlights Atos financial development, SEKbn 2017-2020 revenue and EBITDA margin are reported Atos numbers2 2.2 SEKbn 2020 pro-forma Revenues1 2020 PF is calculated by Coloplast
Slide 39: Atos improves the lives of patients following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective surgery After surgery, a Voice Prosthesis (VP) is inserted by a performed in the advanced stages of cancer healthcare professional, and the patient applies the Heat- and Moisture Exchan
Slide 40: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical procedure that The Tracheostomy patient journey starts with a cannula creates an opening in the neck for direct access insertion, which can be reversed at a
Slide 41: Significant untapped market potential from white space
Significant untapped market potential from “white space”, i.e. low treatment penetration and consumption Key facts Global Laryngectomy market potential1 (DKKbn) • 50,000 new total laryngectomy surgeries performed annually ILLUSTRATIVE • Only ~1/3 of patients undergoing TL surgery are treated with pr
Slide 42: Appendices
Tabitha Leading intimate healthcare LEADING INTIMATE HEALTHCARE Appendices
Slide 43: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Coloplast share listed on Nasdaq Copenhagen since 1983 Share Capital Ownership ~199.9 billion DKK (~30 billion USD) market cap @ ~939.4 DKK 11% per share (incl. A shares) 5% 1% Two share classes: 45% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote
Slide 44: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is 2.3x returned to shareholders through a combination of dividends and share buy- 4,172 backs • Interest bearing debt will only be raised in connection with a major acquisition or other 0.2x 0.3x 0.1x 0.1
Slide 45: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 32.7 36.3 36.2 36.8 31.9 32.3 34.7 34.6 35.3 32.0 31.5 31.7 28.7 29.0 28.1 28.7 28.2 28.9 25.2 24.7 23.4 23.6 23.4 23.7 4.0 4.0 4.2 4.1 3.9 4.4 5.0 5.2 3.8 4.1 3.5 3.9 3.7 3.9 3.9 3.8 3.9 4.0 16/17 17/18 18/19 19/20 20/21 YTD 21/22 16/17
Slide 46: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 9 8 6 6 9 19 6 7 6 13 5 4 10 14 7,841 6 8 8 7,166 9 7,538 10 6,643 5 7 5 6 -7 2,098 1,740 1,970 1,835 2,097 579 17/18 18/19 19/20 20/21 YTD 21/22 17/18 18/19 19/20 20/21 YTD 21/22 Continence Care Wound & Skin Care 8 9
Slide 47: Coloplast revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 6 2 4 8 16 5 6 2 11 4 6 11 8 4 5 9 10,573 10,820 11,261 6 9,941 3 5 3,791 4,380 4,644 4,785 2,959 1,285 17/18 18/19 19/20 20/21 YTD 21/22 17/18 18/19 19/20 20/21 YTD 21/22 Emerging Markets Coloplast group 8 9 4 7 9
Slide 48: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 60 60 59 57 59 2,225 2,330 2,193 2,200 2,156 46 43 37 31 39 42 42 42 42 39 269 269 273 244 239 252 214 224 200 160 Q1 20/21 Q2 20/21 Q3 20/21 Q4 20/21 Q1 21
Slide 49: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2020/21 and hedging policy Revenue FX exposure 2021/22(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -420 USD -170 EUR 36% -290 CNY, JPY, AUD, BRL & ARS 13% GBP -200 HUF 0 120 14% GBP 19% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 50: US Mesh litigation – Overview of financial impact
US Mesh litigation – Overview of financial impact P&L (only special items related to the Mesh litigation Balance Cash flow included) Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,
Slide 51: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC Reimbursement pressure Page 51
Slide 52: CARE helps us increase retention and improve product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 53: With our DtC marketing program we reach into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 53
Slide 54: Generic model for distribution and reimbursement of our products
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance $ Product Page 54
Slide 55: Interventional Urology's revenue is balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 20/21 growing 3-5% annually 11% Coloplast position, FY 20/21 Endourology Men’s Health Women’s Health Bladder H
Slide 56: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S BLADDER HEALTH & ENDOUROLOGY HEALTH HEALTH SURGERY • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 57: Strong presence in our categories but room to capture share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 58: Coloplast acquires Nine Continents Medical Inc
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 59: The global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn RoW Silic
Slide 60: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 61: In US Ostomy Care, innovation is the biggest growth driver
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 62: Awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type 3,6
Slide 63: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products and packaging Reducing emissions Responsible operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products As a growing company, we are challenged Our people and cult
Slide 64: Q1 2021/22 progress on key sustainability ambitions
Q1 2021/22 progress on key sustainability ambitions Improving products and packaging Reducing emissions2 Responsible operations 2025 FY Q1 Q1 2025 FY Q1 Q1 2025 FY Q1 Q1 Ambition 20/21 21/22 20/21 Ambition 20/21 21/22 20/21 Ambition 20/21 21/22 20/21 2.0 2.2 2.3 2.2 90% 23,100 Recyclable 75% Scope 1
Slide 65: Our 2025 priority: Reducing emissions
Our 2025 priority: Reducing emissions We are committed to reducing emissions while being a growth company Scope 3 - Other reported Scope 1 & 2 - Natural gas 2025 target – Scope 1+2 9% and company cars 13% Net-zero 100% Renewable energy (PPAs and phase out Scope 3 – Transportation natural gas use) of
Slide 66: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 67: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products • Market size of DKK ~3bn • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal Brava® Skin Barrier • Main competitors include: Hollister • Designed for leakage • Reducing skin problems Adapt, ConvaTec, 3M Ca
Slide 68: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia (BPH) & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Oth
Slide 69: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Peristeen® Plus Anal Irrigation Faecal incontinence Launched in 2021 + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many •
Slide 70: Introducing Interventional Urology
Introducing Interventional Urology Surgical treatment of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Custo
Slide 71: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues (WSC) Chronic wounds • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Customer groups Wound Care other Contract manufacturing & call points Hospitals Biatain® Silicone Non-Border B
Slide 72: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 73: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 74: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 75: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 76: Income statement
Income statement DKKm Q1 2020/21 Q1 2021/22 Change Revenue 4,738 5,169 9% Gross profit 3,206 3,530 10% SG&A costs -1,495 -1,687 14% R&D costs -186 -205 10% Other operating income/expenses 11 11 0% Operating profit (EBIT) before special items 1,536 1,649 7% Special items - -34 nm Operating profit (EB
Slide 77: Balance sheet
Balance sheet DKKm 31 Dec 2020 31 Dec 2021 Change Balance, total 14,926 16,188 8% Assets Non-current assets 8,286 8,904 7% Current assets 6,640 7,284 10% of which: Inventories 2,231 2,497 12% Trade receivables 2,916 3,215 10% Marketable securities, cash, and cash equivalents 692 864 25% 692 Equity a
Slide 78: Cash flow
Cash flow DKKm Q1 2020/21 Q1 2021/22 Change EBIT 1,536 1,615 5% Amortisation 40 21 -48% Depreciation 162 154 -5% Change in working capital 246 63 -74% Net interest payments 4 -92 nm Paid tax -728 -611 -16% Other -48 -19 -60% Cash flow from operations 1,212 1,131 -7% 1) Investment in intangibles -975
Slide 79: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 12% 0% Mørdrup China 2% Tatabánya Minneapolis Nyirbátor Sarlat US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% 18% Salary - Direct 12% Salary - Indirect 7% Materials (RM &SFG) Innovation & Specialised Pro
Slide 80: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 81: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Sarlat Mankato • Disposable surgica
Slide 82: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 83: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Aleksandra Dimovska Hannah Katrine Larsen Otto Munk Madsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Student Assistant, Investor Relations Tel. direct: +45 49
Slide 84: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /